Alkermes Plc (ALKS) Director Nancy Wysenski Acquires 3,857 Shares of Stock

Alkermes Plc (NASDAQ:ALKS) Director Nancy Wysenski purchased 3,857 shares of the firm’s stock in a transaction on Thursday, February 21st. The stock was bought at an average price of $33.09 per share, for a total transaction of $127,628.13. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of NASDAQ ALKS opened at $34.61 on Tuesday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.63 and a current ratio of 2.89. The stock has a market cap of $5.31 billion, a PE ratio of -494.43 and a beta of 1.82. Alkermes Plc has a 12-month low of $27.54 and a 12-month high of $61.98.

Alkermes (NASDAQ:ALKS) last announced its earnings results on Thursday, February 14th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.39. The firm had revenue of $316.00 million for the quarter, compared to analysts’ expectations of $255.71 million. Alkermes had a negative net margin of 12.73% and a negative return on equity of 0.49%. The business’s revenue was up 14.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.31 EPS. As a group, sell-side analysts expect that Alkermes Plc will post -0.41 EPS for the current year.

Several brokerages have commented on ALKS. Wolfe Research began coverage on shares of Alkermes in a research note on Friday, December 14th. They issued an “underperform” rating on the stock. Stifel Nicolaus decreased their price target on shares of Alkermes from $40.00 to $34.00 and set a “hold” rating on the stock in a research note on Friday, February 15th. TheStreet upgraded shares of Alkermes from a “d” rating to a “c-” rating in a research note on Tuesday, February 19th. Credit Suisse Group upgraded shares of Alkermes to a “hold” rating and set a $30.00 price target on the stock in a research note on Friday, February 15th. Finally, BidaskClub cut shares of Alkermes from a “buy” rating to a “hold” rating in a research note on Friday, January 25th. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $44.15.

Several hedge funds and other institutional investors have recently made changes to their positions in ALKS. Meeder Asset Management Inc. raised its position in shares of Alkermes by 155.3% during the 4th quarter. Meeder Asset Management Inc. now owns 1,810 shares of the company’s stock valued at $53,000 after buying an additional 1,101 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Alkermes by 123.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 2,908 shares of the company’s stock valued at $123,000 after buying an additional 1,608 shares in the last quarter. Quantamental Technologies LLC purchased a new stake in shares of Alkermes during the 4th quarter valued at about $140,000. Nordea Investment Management AB purchased a new stake in shares of Alkermes during the 3rd quarter valued at about $183,000. Finally, LPL Financial LLC purchased a new stake in shares of Alkermes during the 3rd quarter valued at about $212,000. Hedge funds and other institutional investors own 97.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Alkermes Plc (ALKS) Director Nancy Wysenski Acquires 3,857 Shares of Stock” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.chaffeybreeze.com/2019/03/19/alkermes-plc-alks-director-nancy-wysenski-acquires-3857-shares-of-stock.html.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.

See Also: What is a bull market?

Insider Buying and Selling by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.